Phenylacetamides useful as protein kinase inhibitorsCompounds of Formula (I) wherein the residues R1, R2, R3, R9, R10 and Q and X, Y and Z are as defined in the specification, salts thereof; their use, methods of their use, processes for their production, pharmaceutical compositions comprising them, their combinations with second drug substances and the use thereof and the like. The compounds are protein kinase inhibitors and can be used for the treatment of diseases mediated by protein kinase inhibitors, e.g. for the treatment of various proliferative diseases.The compound of formula i,wherein(i) r1 and r2 are selected from hydrogen, halogen and c independently of one another 1-c 7-alkyl; if being n then r3, z do not exist, if perhaps z is that c (carbon) then r3 are hydrogen, unsubstituted or the aryl or the heterocyclic radical unsubstituted or that replace that replace;x is n (nitrogen) or ch (carbon that is replaced by hydrogen),y is ch or n,z is c or n, andq is the group of formula awherein(a) r4 be hydrogen, halogen, the amino that does not replace or replace, the aryl that does not replace or replace, the heterocyclic radical, the cycloalkyl that does not replace or replace, the alkyl that does not replace or replace, the alkenyl that does not replace or replace that do not replace or replaces by the annular atoms bonded beyond the nitrogen or do not replace or the alkynyl of replacement;r5 is 1-methyl-piperidin-4-yl oxygen base, 1-methyl-piperidin-4-yl, 2-dimethylamino-ethyl or 4-ethyl-piperazine-1-base; andthe cycloalkyl that r6 is hydrogen, do not replace or replace or do not replace or the alkyl of (preferably) replacement; or(b) r4 is 1-methyl-piperidin-4-yl methyl, 1-ethyl-piperidin-4-yl methyl, 1-methyl-piperidin-4-yl oxygen base or 1-sec.-propyl-piperidin-4-yl methyl;r5 is a hydrogen, the alkyl that does not replace or replace, the amino that does not replace or replace, the aryl that does not replace or replace or the heterocyclic radical that does not replace or replace; andthe cycloalkyl that r6 is hydrogen, do not replace or replace or do not replace or the alkyl of (preferably) replacement;asterisk * in its chinese style (a) represents that the nh of amide group among this part and the formula i combines by this key; andr9 and r10 are selected from hydrogen, hydroxyl and c independently of one another 1-c 7-alkyl; perhaps r9 and r10 represent oxo together; perhapsr1 and r9 form together-c (o)-ch2-or-ch2-ch2-, r2 is selected from hydrogen, halogen and c 1-c 7-alkyl, and r10 represents hydrogen; or (ii) described compound is selected from:2-(4-benzoglyoxaline-1-base-phenyl)-n-[4-(4-sec.-propyl-piperazine-1-ylmethyl)-3-trifluoromethyl-phenyl]-ethanamide,2-(4-benzoglyoxaline-1-base-phenyl)-n-(4-diethylamino methyl-3-trifluoromethyl-phenyl)-ethanamide),2-(4-benzoglyoxaline-1-base-phenyl)-n-(4-tetramethyleneimine-1-ylmethyl-3-trifluoromethyl-phenyl)-ethanamide,2-(2-chloro-4-imidazo [4,5-b] pyridin-3-yl-phenyl)-n-(4-diethylamino methyl-3-trifluoromethyl-phenyl)-ethanamide,2-(2-chloro-4-imidazo [4,5-b] pyridin-3-yl-phenyl)-n-(4-tetramethyleneimine-1-ylmethyl-3-trifluoromethyl-phenyl)-ethanamide,n-[3-(4-ethyl-piperazine-1-ylmethyl)-5-trifluoromethyl-phenyl]-2-(4-imidazo [4,5-b] pyridin-3-yl-phenyl)-ethanamide,n-(3-diethylamino methyl-5-trifluoromethyl-phenyl)-2-(4-imidazo [4,5-b] pyridin-3-yl-phenyl)-ethanamide,2-(4-benzoglyoxaline-1-base-phenyl)-n-(3-diethylamino methyl-5-trifluoromethyl-phenyl)-ethanamide2-(4-imidazo [4,5-b] pyridin-3-yl-phenyl)-n-[3-(4-methyl-imidazoles-1-yl)-5-trifluoromethyl-phenyl]-ethanamide,2-(4-imidazo [4,5-b] pyridin-3-yl-2-methyl-phenyl)-n-[3-(4-methyl-imidazoles-1-yl)-5-trifluoromethyl-phenyl]-ethanamide,2-(4-imidazo [4,5-b] pyridin-3-yl-2-methyl-phenyl)-n-[3-(4-methyl-piperazine-1-yl)-5-trifluoromethyl-phenyl]-ethanamide,n-[3-(4-ethyl-piperazine-1-ylmethyl)-5-trifluoromethyl-phenyl]-2-(4-imidazo [4,5-b] pyridin-3-yl-2-methyl-phenyl)-ethanamide,2-(2-chloro-4-imidazo [4,5-b] pyridin-3-yl-phenyl)-n-[3-(4-methyl-imidazoles-1-yl)-5-trifluoromethyl-phenyl]-ethanamide,2-(4-benzoglyoxaline-1-base-phenyl)-n-[3-(4-methyl-imidazoles-1-yl)-5-trifluoromethyl-phenyl]-ethanamide,2-(4-benzoglyoxaline-1-base-phenyl)-n-[3-(4-ethyl-piperazine-1-ylmethyl)-5-trifluoromethyl-phenyl]-ethanamide and2-(4-imidazo [4,5-b] pyridin-3-yl-2-methyl-phenyl)-n-[4-(1-methyl-piperidin-4-yl methyl)-3-trifluoromethyl-phenyl]-ethanamide.
단백질 키나제 억제제로서 유용한 페닐아세트아미드본 발명은 하기 화학식 I의 화합물, 그의 염; 그의 용도, 그의 사용 방법, 그의 제조 방법, 그를 포함하는 제약 조성물, 제2 약물 물질과 그의 조합물 및 그의 용도 등에 관한 것이다. 화학식 I의 화합물은 단백질 키나제 억제제이고, 단백질 키나제 억제제에 의해 매개되는 질환의 치료를 위해, 예를 들어 다양한 증식성 질환의 치료를 위해 사용될 수 있다. <화학식 I>  상기 식에서, 잔기 R1, R2, R3, R9, R10 및 Q, 및 X, Y 및 Z는 본 명세서에 정의된 바와 같다.하기 화학식 I의 화합물. <화학식 I> [이미지] 상기 식에서, (i) R1 및 R2는 각각 수소, 할로 및 C1-C7-알킬로 이루어진 군으로부터 서로 독립적으로 선택되고; R3은, Z가 질소라면 존재하지 않거나, 또는 Z가 C (탄소)라면 수소, 비치환 또는 치환된 아릴, 또는 비치환 또는 치환된 헤테로시클릴이고; X는 N (질소) 또는 CH (수소-치환된 탄소)이고; Y는 CH 또는 N이고; Z는 C 또는 N이고; Q는 하기 화학식 A의 기이고; <화학식 A> [이미지] (상기 식에서, (a) R4는 수소, 할로, 비치환 또는 치환된 아미노, 비치환 또는 치환된 아릴, 질소 이외의 고리 원자를 통해 결합된 비치환 또는 치환된 헤테로시클릴, 비치환 또는 치환된 시클로알킬, 비치환 또는 치환된 알킬, 비치환 또는 치환된 알케닐, 또는 비치환 또는 치환된 알키닐이고; R5는 1-메틸-피페리딘-4-일옥시, 1-메틸-피페리딘-4-일, 2-디메틸아미노-에틸 또는 4-에틸-피페라진-1-일이고; R6은 수소, 비치환 또는 치환된 시클로알킬, 또는 비치환 또는 (바람직하게는) 치환된 알킬이거나; 또는 (b) R4는 1-메틸-피페리딘-4-일메틸, 1-에틸-피페리딘-4-일메틸, 1-메틸-피페리딘-4-일옥시 또는 1-이소프로필-피페리딘-4-일메틸이고; R5는 수소, 비치환 또는 치환된 알킬, 비치환 또는 치환된 아미노, 비치환 또는 치환된 아릴, 또는 비치환 또는 치환된 헤테로시클릴이고; R6은 수소, 비치환 또는 치환된 시클로알킬, 또는 비치환 또는 (바람직하게는) 치환된 알킬이며; 화학식 A에서 별표 *는 결합을 표시하는데, 이 결합을 통해 화학식 I의 아미드기의 NH에 잔기가 결합됨) R9 및 R10은 각각 수소, 히드록실 및 C1-C7-알킬로 이루어진 군으로부터 서로 독립적으로 선택되거나; 또는 R9 및 R10은 함께 옥소를 나타내거나; 또는 R1 및 R9는 함께 -C(O)-CH2- 또는 -CH2-CH2- 기를 형성하고, R2는 수소, 할로 및 C1-C7-알킬로 이루어진 군으로부터 선택되고, R10은 수소를 나타내거나; 또는 (ii) 화학식 I의 화합물은 2-(4-벤조이미다졸-1-일-페닐)-N-[4-(4-이소프로필-피페라진-1-일메틸)-3-트리플루오로메틸-페닐]-아세트아미드, 2-(4-벤조이미다졸-1-일-페닐)-N-(4-디에틸아미노메틸-3-트리플루오로메틸-페닐)-아세트아미드), 2-(4-벤조이미다졸-1-일-페닐)-N-(4-피롤리딘-1-일메틸-3-트리플루오로메틸-페닐)-아세트아미드, 2-(2-클로로-4-이미다조[4,5-b]피리딘-3-일-페닐)-N-(4-디에틸아미노메틸-3-트리플루오로메틸-페닐)-아세트아미드, 2-(2-클로로-4-이미다조[4,5-b]피리딘-3-일-페닐)-N-(4-피롤리딘-1-일메틸-3-트리플루오로메틸-페닐)-아세트아미드, N-[3-(4-에틸-피페라진-1-일메틸)-5-트리플루오로메틸-페닐]-2-(4-이미다조[4,5-b]피리딘-3-일-페닐)-아세트아미드, N-(3-디에틸아미노메틸-5-트리플루오로메틸-페닐)-2-(4-이미다조[4,5-b]피리딘-3-일-페닐)-아세트아미드, 2-(4-벤조이미다졸-1-일-페닐)-N-(3-디에틸아미노메틸-5-트리플루오로메틸-페닐)-아세트아미드, 2-(4-이미다조[4,5-b]피리딘-3-일-페닐)-N-[3-(4-메틸-이미다졸-1-일)-5-트리플루오로메틸-페닐]-아세트아미드, 2-(4-이미다조[4,5-b]피리딘-3-일-2-메틸-페닐)-N-[3-(4-메틸-이미다졸-1-일)-5-트리플루오로메틸-페닐]-아세트아미드, 2-(4-이미다조[4,5-b]피리딘-3-일-2-메틸-페닐)-N-[3-(4-메틸-피페라진-1-일)-5-트리플루오로메틸-페닐]-아세트아미드, N-[3-(4-에틸-피페라진-1-일메틸)-5-트리플루오로메틸-페닐]-2-(4-이미다조[4,5-b]피리딘-3-일-2-메틸-페닐)-아세트아미드, 2-(2-클로로-4-이미다조[4,5-b]피리딘-3-일-페닐)-N-[3-(4-메틸-이미다졸-1-일)-5-트리플루오로메틸-페닐]-아세트아미드, 2-(4-벤조이미다졸-1-일-페닐)-N-[3-(4-메틸-이미다졸-1-일)-5-트리플루오로메틸-페닐]-아세트아미드, 2-(4-벤조이미다졸-1-일-페닐)-N-[3-(4-에틸-피페라진-1-일메틸)-5-트리플루오로메틸-페닐]-아세트아미드 및 2-(4-이미다조[4,5-b]피리딘-3-일-2-메틸-페닐)-N-[4-(1-메틸-피페리딘-4-일메틸)-3-트리플루오로메틸-페닐]-아세트아미드 로 이루어진 군으로부터 선택된다.